CVAC יחס מהיר CureVac N.V.

Serving as a valuation tool, the CureVac N.V. (CVAC) price chart on GURU.Markets, where the indicator stands at 3.87, is backed by a team of top German biologists. The development strategy relies on partnerships with industry behemoths to create anti-tumor drugs, which mitigates the narrow specialization in mRNA. The company's fundamental potential is based on a second-generation innovative platform that guarantees drug stability without refrigeration and significant pricing power.

This indicator measures the ability of CureVac N.V. (CVAC) to settle short-term liabilities using its most liquid assets, excluding hard-to-liquidate inventories. Analyzing short-term solvency excluding inventories reveals whether cash and accounts receivable are sufficient to fund mRNA development and cancer therapies, which is critical when executing large-scale partnerships with global pharma behemoths.